Prevention of cytomegalovirus disease in patients with impaired cell-mediated immunity – is there a need for maribavir?

Bibliography

• Eid AJ, Razonable RR. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 2010;70:965-81
   PubMed Web of Science ®Google Scholar
• Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010;89:779-95
   PubMed Web of Science ®Google Scholar
• Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect Dis Clin North Am 2010;24:319-37
   PubMed Web of Science ®Google Scholar
• Hantz S, Garnier-Geoffroy F, Mazeron MC, et al. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J Antimicrob Chemother 2010;65:2628-40
   PubMed Web of Science ®Google Scholar
• Couzi L, Helou S, Bachelet T, et al. High incidence of anticytomegalovirus drug resistance among D+R- kidney transplant recipients receiving preemptive therapy. Am J Transplant 2011;12:202-9
   PubMedGoogle Scholar
• van der Beek MT, Berger SP, Vossen AC, et al. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance. Transplantation 2010;89:320-6
   PubMed Web of Science ®Google Scholar
• Humar A, Limaye AP, Blumberg EA, et al. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation 2010;90:1427-31
   PubMed Web of Science ®Google Scholar
• Kern ER, Hartline C, Harden E, et al. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob Agents Chemother 2002;46:991-5
   PubMed Web of Science ®Google Scholar
• Painter WRA, Trost LA, Godkin S, et al. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Antimicrob Agents Chemother 2012;56:2726-34
   PubMed Web of Science ®Google Scholar
• Lischka P, Hewlett G, Wunberg T, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob.Agents Chemother 2010;54:1290-7
   PubMed Web of Science ®Google Scholar
• Goldner T, Hewlett G, Ettischer N, et al. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol 2011;85:10884-93
   PubMed Web of Science ®Google Scholar
• Marschall M, Stamminger T, Urbani A, et al. In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses. Antimicrob Agents Chemother 2012;56:1137
   Google Scholar
• Kaul DR, Stoelben S, Cober E, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant 2011;11:1079-84
   PubMed Web of Science ®Google Scholar
• James SH, Hartline CB, Harden EA, et al. Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase. Antimicrob Agents Chemother 2011;55:4682-91
   PubMedGoogle Scholar
• Chou S, Bowlin TL. Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. Antimicrob Agents Chemother 2011;55:382-4
   PubMedGoogle Scholar
• Gentry BG, Vollmer LE, Hall ED, et al. Resistance of human cytomegalovirus to cyclopropavir maps to a base pair deletion in the open reading frame of UL97. Antimicrob Agents Chemother 2013;57:4343-8
   PubMed Web of Science ®Google Scholar
• Wolf DG, Shimoni A, Resnick IB, et al. Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation. Antiviral Res 2011;90:183-6
   PubMed Web of Science ®Google Scholar
• Lau PK, Woods ML, Ratanjee SK, John GT. Artesunate is ineffective in controlling valganciclovir-resistant cytomegalovirus infection. Clin Infect Dis 2011;52:279
   PubMed Web of Science ®Google Scholar
• Gantt S, Huang ML, Magaret A, et al. An artesunate-containing antimalarial treatment regimen did not suppress cytomegalovirus viremia. J Clin Virol 2013;58:276-8
   PubMedGoogle Scholar
• Waldman WJ, Knight DA, Blinder L, et al. Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology 1999;42:412-18
   PubMed Web of Science ®Google Scholar
• Avery RK, Bolwell BJ, Yen-Lieberman B, et al. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplant 2004;34:1071-5
   PubMed Web of Science ®Google Scholar
• Battiwalla M, Paplham P, Almyroudis NG, et al. Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. Transpl Infect Dis 2007;9:28-32
   PubMed Web of Science ®Google Scholar
• Avery RK, Mossad SB, Poggio E, et al. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation 2010;90:419-26
   PubMed Web of Science ®Google Scholar
• Townsend LB, Devivar RV, Turk SR, et al. Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(beta-D-ribofuranosyl)benzimidazoles. J Med Chem 1995;38:4098-105
   PubMed Web of Science ®Google Scholar
• Underwood MR, Harvey RJ, Stanat SC, et al. Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product. J Virol 1998;72:717-25
   PubMed Web of Science ®Google Scholar
• Williams SL, Hartline CB, Kushner NL, et al. In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob Agents Chemother 2003;47:2186-92
   PubMed Web of Science ®Google Scholar
• Drew WL, Miner RC, Marousek GI, Chou S. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol 2006;37:124-7
   PubMed Web of Science ®Google Scholar
• McSharry JJ, McDonough A, Olson B, et al. Inhibition of ganciclovir-susceptibe and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94. Clin Diagn Lab Immunol 2001;8:1279-81
   PubMedGoogle Scholar
• Michel D, Mertens T. The UL97 protein kinase of human cytomegalovirus and homologues in other herpesviruses: impact on virus and host. Biochim Biophys Acta 2004;1697:169-80
   PubMedGoogle Scholar
• Sullivan V, Talarico CL, Stanat SC, et al. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 1992;358:162-4
   PubMed Web of Science ®Google Scholar
• Hamirally S, Kamil JP, Ndassa-Colday YM, et al. Viral mimicry of Cdc2/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus egress. PLoS ONE 2009;5:e1000275
   Google Scholar
• Krosky PM, Baek MC, Coen DM. The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J Virol 2003;77:905-14
   PubMed Web of Science ®Google Scholar
• Schreiber A, Harter G, Schubert A, et al. Antiviral treatment of cytomegalovirus infection and resistant strains. Expert Opin Pharmacother 2009;10:191-209
   PubMed Web of Science ®Google Scholar
• Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010;23:689-12
   PubMed Web of Science ®Google Scholar
• Michel D, Pavic I, Zimmermann A, et al. The UL97 gene product of the human cytomegalovirus is an early-late protein with a nuclear localization but is not a nucleoside kinase. J Virol 1996;70:6340-7
   PubMed Web of Science ®Google Scholar
• Michel D, Schaarschmidt P, Wunderlich K, et al. Functional regions of the human cytomegalovirus protein pUL97 involved in nuclear localization and phosphorylation of ganciclovir and pUL97 itself. J Gen Virol 1998;79:2105-12
   PubMedGoogle Scholar
• Michel D, Kramer S, Hohn S, et al. Amino acids of conserved kinase motifs of cytomegalovirus protein UL97 are essential for autophosphorylation. J Virol 1999;73:8898-01
   PubMedGoogle Scholar
• Hakki M, Chou S. The biology of cytomegalovirus drug resistance. Curr Opin Infect Dis 2011;24:605-11
   PubMed Web of Science ®Google Scholar
• Chou S, Marousek GI. Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus. Antimicrob Agents Chemother 2006;50:3470-2
   PubMed Web of Science ®Google Scholar
• Chan JH, Chamberlain SD, Biron KK, et al. Synthesis and evaluation of a series of 2'-deoxy analogues of the antiviral agent 5,6-dichloro-2-isopropylamino-1-(beta-L-ribofuranosyl)-1H-benzimidazole (1263W94). Nucleosides Nucleotides Nucleic Acids 2000;19:101-23
   PubMed Web of Science ®Google Scholar
• Chou S, Wechel LC, Marousek GI. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. J Infect Dis 2007;196:91-4
   PubMed Web of Science ®Google Scholar
• Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev Med Virol 2008;18:233-46
   PubMed Web of Science ®Google Scholar
• Avery RK, Marty FM, Strasfeld L, et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis 2010;12:489-96
   PubMed Web of Science ®Google Scholar
• Strasfeld L, Lee I, Tatarowicz W, et al. Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir. J Infect Dis 2010;202:104-8
   PubMed Web of Science ®Google Scholar
• Schubert A, Ehlert K, Schuler-Luettmann S, et al. Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient. BMC Infect Dis 2013;13:330
   PubMed Web of Science ®Google Scholar
• Komazin G, Ptak RG, Emmer BT, et al. Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27. J Virol 2003;77:11499-06
   PubMed Web of Science ®Google Scholar
• Chou S, Marousek GI, Senters AE, et al. Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. J Virol 2004;78:7124-30
   PubMed Web of Science ®Google Scholar
• Prichard MN, Quenelle DC, Bidanset DJ, et al. Human cytomegalovirus UL27 is not required for viral replication in human tissue implanted in SCID mice. Virol J 2013;3:18-12
   Google Scholar
• Koszalka GW, Johnson NW, Good SS, et al. Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother 2002;46:2373-80
   PubMed Web of Science ®Google Scholar
• Wang LH, Peck RW, Yin Y, et al. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2003;47:1334-42
   PubMed Web of Science ®Google Scholar
• Lalezari JP, Aberg JA, Wang LH, et al. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob Agents Chemother 2002;46:2969-76
   PubMed Web of Science ®Google Scholar
• Swan SK, Smith WB, Marbury TC, et al. Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of renal impairment. J Clin Pharmacol 2007;47:209-17
   PubMedGoogle Scholar
• Ma JD, Nafziger AN, Villano SA, et al. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob Agents Chemother 2006;50:1130-5
   PubMedGoogle Scholar
• Pescovitz MD, Bloom R, Pirsch J, et al. A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients. Am J Transplant 2009;9:2324-30
   PubMed Web of Science ®Google Scholar
• Biron KK, Harvey RJ, Chamberlain SC, et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother 2002;46:2365-72
   PubMed Web of Science ®Google Scholar
• Wiltshire H, Hirankarn S, Farrell C, et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet 2005;44:495-507
   PubMed Web of Science ®Google Scholar
• Wiltshire H, Paya CV, Pescovitz MD, et al. Pharmacodynamics of oral ganiclovir and valganciclovir in solid organ transplant patients. Transplantation 2005;79:1477-83
   PubMed Web of Science ®Google Scholar
• Winston DJ, Young JA, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 2008;111:5403-10
   PubMed Web of Science ®Google Scholar
• Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 2011;11:284-92
   PubMed Web of Science ®Google Scholar
• Winston DJ, Saliba F, Blumberg E, et al. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am J Transplant 2013;12:3021-30
   Google Scholar
• Marty FM, Boeckh M. Maribavir and human cytomegalovirus - what happened in the clinical trials and why might the drug have failed? Curr Opin Virol 2011;1:555-62
   PubMed Web of Science ®Google Scholar
• Alain S, Revest M, Veyer D, et al. Maribavir use in practice for cytomegalovirus infection in French transplantation centers. Transplant Proc 2013;45:1603-7
   PubMed Web of Science ®Google Scholar